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Background: Despite the early theoretical prediction of the 0+-0+ transition of 90Zr, 90Y-PET underwent only
recently a growing interest for the development of imaging radioembolization of liver tumors. The aim of this work
was to determine the minimum detectable activity (MDA) of 90Y by PET imaging and the impact of time-of-flight
(TOF) reconstruction on detectability and quantitative accuracy according to the lesion size.
Methods: The study was conducted using a Siemens BiographW mCT with a 22 cm large axial field of view. An IEC
torso-shaped phantom containing five coplanar spheres was uniformly filled to achieve sphere-to-background ratios
of 40:1. The phantom was imaged nine times in 14 days over 30 min. Sinograms were reconstructed with and
without TOF information. A contrast-to-noise ratio (CNR) index was calculated using the Rose criterion, taking partial
volume effects into account. The impact of reconstruction parameters on quantification accuracy, detectability, and
spatial localization of the signal was investigated. Finally, six patients with hepatocellular carcinoma and four
patients included in different 90Y-based radioimmunotherapy protocols were enrolled for the evaluation of the
imaging parameters in a clinical situation.
Results: The highest CNR was achieved with one iteration for both TOF and non-TOF reconstructions. The MDA,
however, was found to be lower with TOF than with non-TOF reconstruction. There was no gain by adding TOF
information in terms of CNR for concentrations higher than 2 to 3 MBq mL−1, except for infra-centimetric lesions.
Recovered activity was highly underestimated when a single iteration or non-TOF reconstruction was used (10% to
150% less depending on the lesion size). The MDA was estimated at 1 MBq mL−1 for a TOF reconstruction and
infra-centimetric lesions. Images from patients treated with microspheres were clinically relevant, unlike those of
patients who received systemic injections of 90Y.
Conclusions: Only one iteration and TOF were necessary to achieve an MDA around 1 MBq mL−1 and the most
accurate localization of lesions. For precise quantification, at least three iterations gave the best performance, using
TOF reconstruction and keeping an MDA of roughly 1 MBq mL−1. One and three iterations were mandatory to
prevent false positive results for quantitative analysis of clinical data.
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Yttrium-90 (half-life, 64 h) is a radionuclide used in targeted
radionuclide therapy, particularly for radioimmunotherapy
(RAIT), peptide receptor radionuclide therapy (PRRT), and
selective internal radiotherapy (SIRT). Promising clinical
results have been obtained for the treatment of B-cell
lymphomas with anti-CD20 and anti-CD22 monoclonal
antibodies [1,2], while the treatment of neuroendocrine
tumors with somatostatin analogues has proven its benefit
in the last decade [3,4]. One RAIT product labeled with 90Y
has been already approved by the regulatory authorities
(ZevalinW, Bayer Corporation, Pittsburgh, USA). Encasing
90Y in a resin or a glass sphere has also provided a promis-
ing approach for the treatment of hepatocellular carcinoma
(HCC) and unresectable liver metastases with SIRT [5-7].
Two microsphere products are approved and available for
clinical practice: TheraSphereW (glass microspheres; MDS
Nordion, Ontario, Canada) and SIR-SpheresW (resin
microspheres; Sirtex Medical, North Sydney, Australia).
The emission spectrum of 90Y is almost exclusively β−
(mean energy 933.6 keV), making the irradiation of
macroscopic tumoral lesions possible. However, despite
the increasing therapeutic applications of 90Y, imaging
the distribution of this isotope in the patient's body
remains a significant challenge when assessing the qual-
ity of tumor targeting after injection, as well as when
performing systematic dosimetry studies. While pre-
therapeutic imaging with surrogate tracers remains the
best and only means of adapting the therapeutic activity
to be injected (such as 111In or 68 Ga for RAIT or 99mTc
for SIRT), it could pose significant organizational issues
depending on local constraints (especially for 111In pre-
therapeutic studies) as well as additional costs. More-
over, the biodistribution of a radiopharmaceutical labeled
with a different radionuclide may imperfectly predict
that of 90Y-labeled radiopharmaceuticals [8]. Therefore,
in vivo imaging during the treatment phase can predict
toxicity and efficacy, and can help optimize the injected
activity in subsequent courses, given that radiotherapy
treatments usually require repeat injections.
The current clinical practice for in vivo imaging of such
treatment involves a SPECTacquisition using bremsstrahl-
ung and remains the method of choice to assess the distri-
bution of 90Y-labeled radiopharmaceuticals [9]. Although
reconstruction algorithms suitable for bremsstrahlung im-
aging of 90Y are under development [9,10], the resulting
images have the disadvantage of having a low spatial reso-
lution and poor quantification performance, especially for
small lesions when using parallel-hole collimators. How-
ever, a recent study showed the benefits of a using pinhole
collimator for bremsstrahlung imaging of 90Y with very
promising results [11].
The prediction and discovery of the 0+-0+ transition of
90Zr [12], which results in a β+/β− pair creation with avery low branching ratio of 31.86 × 10−6 [13], provide
the opportunity to detect 90Y distribution using PET
images [14]. The first clinical applications of PET im-
aging with 90Y have been tested recently in the context
of radioembolization [15,16], PRRT [17], and RAIT for
lymphoma [18]. These studies focused primarily on the
detection of lesions incorporating a very large amount of
tracer (typically several MBq mL−1, equivalent to several
tens of Bq mL−1 when considering the pair creation),
thus facilitating the visualization and accurate measure-
ment of radioactive concentration. Similarly, the value of
using time of flight (TOF) information for this type of
acquisition in this context of high radioactive concentra-
tion was recently investigated [19]. In a RAIT protocol,
the expected concentration in the lesions generally
ranges from 0.01% or less to 1% of the total injected ac-
tivity. This leads to a typical concentration of several
tens of kBq mL−1 [20].The aim of this work was three-
fold. The first objective was to determine the minimum
detectable activity (MDA) with PET imaging using 90Y
for a LSO-based acquisition system in relation to lesion
size. The second objective was to study the impact of
TOF reconstruction on detectability and quantitative ac-
curacy according to lesion size and finally to correlate
these results with analysis on patient data.
Methods
PET/CT system
The whole study was conducted using the PET/CT
BiographW mCT 40 (Siemens Healthcare Molecular Im-
aging, Hoffman Estates, IL, USA). The patient bore
aperture was 78 cm (inner diameter 84.2 cm) with an
axial field of view (FOV) of 22 cm. The system was
equipped with 32,448 LSO crystals (4 × 4 × 20 mm3).
The detection energy window was set to 435 to 650 keV
for a coincidence window of 4.1 ns. The system was
able to record TOF information between two events in
coincidence. Given the sufficient count rate capacity of
the system [21] confirmed by in-house performance
measurements of count losses according to the NEMA
NU 2–2007 methods [22], it was chosen to not incorp-
orate a copper ring between the source and the LSO
crystals to lower the count rate originating from the
bremsstrahlung [19,23].
Phantom study
Source preparation and acquisition protocol
A standard IEC/NEMA 2001 torso-shaped phantom
(PTW Freiburg GmbH, Freiburg, Germany) was used
with five spheres (internal diameters 10, 13, 17, 22,
and 28 mm). The spheres were initially filled with free
90Y (8100 ± 5% kBq mL−1). The phantom volume (9.1 L)
was also filled uniformly with an initial activity of 90Y
(200 ± 5% kBq mL−1) to simulate a sphere-to-background
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simulate a high tumor uptake relative to the background
typically encountered in a RAIT procedure. Acquisition of
the phantom was performed nine times over 14 days,
starting from an initial activity concentration in the
spheres of 6,740 kBq mL−1 decreasing to 490 kBq mL−1.
All measurements were performed over a duration of
30 min using a single-bed position including the whole
phantom in the FOV.
Reconstruction
The acquisitions were reconstructed with the proprietary
implementation of the point spread function (PSF) ordinary
Poisson (OP) ordered subset expectation maximization (3D
OP-OSEM PSF) available for this scanner [24]. We have
used both TOF and non-TOF reconstructions with respect-
ively 21 and 24 subsets, which are the clinical default
settings. One or three iterations were used for both TOF
and non-TOF reconstructions to assess the impact of
increasing the number of iterations on the sphere detec-
tion and quantification accuracies. A maximum of three
iterations was set in order to limit noise amplification.
Additional parameters such as the impact of two iterations
were omitted as the study was limited to evaluating the
trade-off between detectability and quantification. Datasets
were reconstructed into standard 200 × 200 × 109 matrix
size using a 4 × 4 × 2 mm3 voxel size. A 3D Gaussian post-
smoothing of 2 mm full-width at half maximum (FWHM)
was applied. To allow direct comparison, all reconstructed
images were coregistered to the image corresponding to the
first acquisition. This was facilitated by placing the phantom
at identical axial and transaxial positions using laser lights
of the system and markings made on the phantom.
Data processing
Detectability
The detectability was assessed using a contrast-to-noise
ratio (CNR) based figure of merit (FOM), and its formal-
ism is given below. As mentioned before, the branching
ratio of internal pair creation for 90Zr is remarkably
small compared to usual PET tracers. The detection of
lesions incorporating 90Y, therefore, is challenged by very
low levels of radioactive distribution, or signal. In this re-
spect, the determination of a MDA has been the subject of
several studies in preclinical situations [25,26]. The MDA
may be evaluated using the Rose criterion [27]. It states




where CL, CB, and σB are the lesion, the background, and
the background noise intensities, respectively.The background noise σB
r measured inside a given re-











Here, m^r is the average of activity for the V voxels in-
side the ROI Rr in the reconstructed image f. The final
noise FOM was measured in R ROIs in the background





The R = 20 ROIs localized in the background were
randomly chosen, in such a way that they were separated
by at least two voxels from each other and at least three
voxels from the phantom border. Each ROI consisted of
V = 32 voxels. The transverse slice aligned with all
sphere centers was chosen for analysis.
This FOM proved to be equivalent to a rigorous noise as-
sessment using multiple statistically independent replicates
while avoiding the correlation between voxels that results
from iterative reconstruction [28].
The relation (1) is established for a signal present in a
single voxel. However, it can be extended to a lesion
covering N voxels [25] using the equation:







where PVE is the partial volume effect calculated for
each sphere. The PVE was evaluated with an 18 F-based
acquisition with similar phantom preparation, by drawing
a circular ROI with an internal diameter equal to the ac-
tual diameter of the spheres. For this setup, the SBR was
chosen identical to that of the 90Y-based acquisitions. The
measurement was repeated 30 times to supply 30 inde-
pendent datasets. The mean PVE was derived from these
30 datasets.
As the spheres were close to a circular-shaped object,
we chose to modify the limit of detectability for CNR
according to a previous work based on human observers
[29]. Although determined in the different context of
simulated noisy micrographs, they have suggested that
circular-shaped object was detected if CNR > 8 for an
area equivalent to those considered in the present work.
Thus, this limit will be considered in this work.
Recovered activity in the spheres
The total activity in each sphere was calculated for each
of the nine 90Y-based acquisitions and was compared to
the theoretical value as a percentage of recovered activ-
ity. The total activity in a sphere was computed as the
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(VOI) corresponding to the sphere. The VOI for each
sphere was determined from the sum image of the 30 18 F-
based independent acquisitions mentioned earlier for PVE
determination. The five VOIs were calculated using a
threshold relative to the maximum value in the VOI. The
intensity threshold was chosen to obtain the smallest
difference between the true volume and the measured
volume.
Spatial distribution of the signal in spheres
The reconstruction of a very weak signal can be signifi-
cantly biased when assessing its spatial distribution. The
change in the distribution of the signal within the
spheres according to the radioactive concentration was
evaluated by calculating the root mean square error
(RMSE) using the following equation:
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where BS
90Y
k denotes the contents of voxel k in a sphere
for the yttrium-based acquisition, and BS
18F
k represents
fluorine-based acquisition. The signal considered for the
fluorine-based acquisition was measured from a mean
image computed from the 30 independent acquisitions
described in the ‘Recovered activity in the spheres’ sec-
tion. For the RMSE calculation, the images were first
normalized by the mean signal for each acquisition and
for each sphere considered.
Count rate
The acquisition of a weak signal may be masked by natural
radioactivity of 176Lu in LSO crystals (about 2.59% of the
lutetium element). The background signal generated by
176Lu can contribute to the amount of random and true
coincidences [26,30]. For each acquisition, prompt and
random coincidence rates were measured. A long acquisi-
tion (approximately 900,000 registered true coincidences)
with no activity present in the field of view was performed
to determine the 176Lu background count rate.
Patient study
A clinical study was performed on ten patients, includ-
ing six patients with HCC treated by hepatic SIRT
using TheraSphereW (MDS Nordion) or SIR-SpheresW
(Sirtex Medical), and four patients with B lymphoma
treated using anti-CD20 ZevalinW (Bayer) or anti-CD22
epratuzumab (Immunomedics, Inc., Morris Plain, NJ, USA)
90Y-based RAIT. Among the six HCC patients, five had
macroscopic lesions, and one had a diffuse liver disease.
Among the four lymphoma patients, two had a diffuse large
B-cell lymphoma, and one had a follicular lymphomareceiving RAIT as consolidation treatment after an induc-
tion therapy. The other patient had a follicular lymphoma
and was undergoing first-line treatment with ZevalinW
(Bayer). All patients underwent a 30-min PET imaging ses-
sion with all acquisition parameters identical to those of
the phantom study. Reconstructions were performed with
or without TOF information with one or three iterations.
For those who underwent radioembolization, the total
amount of reconstructed activity was compared to the the-
oretical activity injected to the patient, as measured by the
dose calibrator before injection.
All patients gave informed written consent in accord-
ance with institutional guidelines, including the declar-
ation of Helsinki. The trials were approved by the
responsible ethics committee.
Results
Detectability and minimum detectable activity
Figure 1 shows the detectability performance on phantom
for both TOF and non-TOF reconstructions and one or
three iterations. When reconstruction was made with
TOF, higher detectability was reached with a small num-
ber of iterations (one iteration with 21 subsets), regardless
of the sphere size. This result held true for non-TOF
reconstructions with a less marked difference between one
and three iterations. All spheres with a diameter greater
than 17 mm were detected regardless of the radioactive
concentration in the spheres considered in this study for
TOF reconstruction (22 mm for non-TOF).
The MDA for the smaller volume was about 1 MBq mL−1
for TOF reconstructions (and 3 MBq mL−1 for non-TOF)
when using reconstructions with a single iteration. Despite
an absolute value greater than 1 for the normalized CNR,
determining the MDA for this smallest sphere reconstructed
without TOF was particularly difficult. This was due to
the slow decrease in the CNR with the radioactive concen-
tration, as well as the high noise in the background
discussed above. Consequently, a comparison between the
qualitative analysis of reconstructed images and the quan-
titative values (CNR) was taken into account to calculate
the actual MDA for the smallest sphere and the non-TOF
reconstruction case.
The benefit of adding TOF information is illustrated in
Figure 1 for spheres of diameters 17 and 13 mm. Taking
into account statistical fluctuations, we observed no signifi-
cant gain in using TOF for small structures more than
17 mm in diameter and concentrations greater than ap-
proximately 2 to 3 MBq mL−1 when using one iteration for
the CNR figure of merit. As expected, smaller structures
lead to an improved MDA for TOF reconstructions regard-
less of the activity concentration.
Figure 2 shows the slice crossing all spheres at their lar-
gest diameter for the nine acquisitions performed. All
spheres remain clearly visible down to a concentration of
Figure 1 CNR normalized by the minimum CNR value. CNR normalized by the minimum CNR value (8) according to the activity
concentration in all spheres for TOF reconstruction (A), non-TOF reconstruction (B), the 13-mm diameter (C), and the 17-mm diameter sphere (D).
The thick line ( in panels A and B) is the minimum normalized CNR value (1) above which the detectability could be considered as true.
Experimental data points were fitted to highlight the relationship between CNR and activity concentration.
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For the same number of iterations, the smallest sphere
(10 mm in diameter) was no longer visible below a
concentration of 3 MBq mL−1. In general, the change
from one to three iterations substantially increased the
noise in the reconstructed images and made visual de-
tection difficult for radioactive concentrations below
3 MBq mL−1.
Recovered activity in the spheres
Figure 3 shows the percentage of activity reconstructed for
the two spheres of 17 and 28 mm only. The trend for
reconstructed activities in relation to the activity concentra-
tion within spheres was similar for all spheres. When the
TOF information was used during reconstruction, oneiteration gave a slight underestimation (less than 5%)
compared to the results obtained with three iterations, ex-
cept for the activity concentrations below 1 MBq mL−1
where the underestimation was greater than 10%. The non-
TOF reconstructions performed with a single iteration
underestimated the activity concentration in the spheres by
between 10% and 20% compared to TOF reconstruction
with three iterations for large structures (more than 22 mm
in diameter) when the activity concentration was greater
than 3 MBq mL−1. This underestimation reached more
than a factor of 2 for small structures (less than 17 mm in
diameter) or concentrations below 1 MBq mL−1.
Finally, TOF reconstructions with one iteration
and non-TOF with three iterations gave very similar
results.







Figure 2 Central slice of the phantom. Transverse slice passing through the middle of the spheres for TOF and non-TOF reconstructions as a
function of activity concentration in the spheres. The background gray scale is identical for all images.
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Figure 4 shows the RMSE according to activity concen-
tration for both spheres of 17 and 28 mm in diameter.
The conclusions were equivalent for other spheres.
The mean RMSE calculated based on three independent
18 F-based acquisitions is represented by a dotted line in
order to estimate the minimum value achievable for theFigure 3 Recovered activity. Percentage of recovered activity according
diameter spheres (B). Experimental data points were fitted to highlight theRMSE. As suggested by the images (Figure 2), a lower
radioactive concentration led to a higher RMSE. This
resulted in substantial errors for radioactive concentrations
of less than about 1 MBq mL−1. Again, TOF reconstruction
with one iteration gave results closest to the expected
spatial distribution regardless of the radioactive concentra-
tion for a homogeneous activity distribution.to the activity concentration for the 17-mm diameter (A) and 28-mm
relationship between recovered activity and activity concentration.
Figure 4 Root mean square error. RMSE according to the activity concentration for the 17-mm diameter (A) and 28-mm diameter (B) spheres.
The two dotted lines represent the minimal RMSE calculated with three independent 18 F-based acquisitions.
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Despite the extended field of view with a large accept-
ance of 13.2 for incoming single events, no saturation
of the detectors was observed, which is in accordance
with previous studies using similar systems [19]. Figure 5
shows the count rate of prompt, delayed, and true
coincidences for the total activity (including background
and spheres). The dotted horizontal line shows the
count rate of delayed coincidences due to the contribu-
tion of 176Lu. The count rate of true coincidences when
no source was located in the field of view was 5 cps for
the default acquisition setup of the scanner. The total
activity of 176Lu contained in the 32,448 crystals of the
BiographW mCT (Siemens AG, Munich, Germany) was
estimated at about 2.6 MBq. The total useful signalFigure 5 Count rate. Count rate according to total activity in the field of
count rate for random coincidences.(prompt coincidences) was still significantly greater than
the residual 176Lu background noise for activities
exceeding 400 MBq in the field of view (greater than one
standard deviation of the Poisson noise). As a comparison,
the ratio between the prompt and random coincidence
rates for a standard 18 F-FDG scan was approximately 3
for a step centered on the liver. This ratio was roughly 1.2
for 1.5 GBq of 90Y centered in the FOV. This highlights
the importance of having an unbiased estimate of random
coincidences for low count rates such as those typically
encountered for 90Y imaging [30].
Patient results
No 90Y uptake was detected using PET in the four lymph-
oma patients. Three of them had small tumor masses afterview of the scanner. The blue dotted line shows the natural 176Lu
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cutaneous disease but no masses. For the six HCC
patients, high radioactive concentration in the tumors was
detected using 90Y-PET, distinguishing tumors of different
sizes. The benefit of performing an 90Y-PET acquisition in
the context of HCC disease is illustrated in Figure 7 for
two different patients. One patient showed a good agree-
ment between the 99mTc-labeled macroaggregates (99mTc-
MAA) SPECT scan, the bremsstrahlung SPECT scan, and
the 90Y-PET acquisition. The other exhibited a clear dis-
crepancy between the pre-treatment 99mTc-MAA SPECT
scan and post-therapeutic acquisitions due to a slight dif-
ference between injection techniques and an asymmetric
arterial flow. No tumor uptake was detected with the
bremsstrahlung image, while 90Y-PET imaging clearly
highlighted a small uptake by the tumor. This example
clearly highlights the benefit of using 90Y-PET for small
lesions compared to bremsstrahlung imaging. Moreover,
the activity concentration for this small tumor (1.5 cm3)
was measured with one iteration and TOF (1.1 MBq mL−1),
three iterations and non-TOF (1.3 MBq mL−1), and three
iterations and TOF (2.2 MBq mL−1) reconstructions. In
this case, the difference could reach a factor 2 between
the different sets of reconstruction parameters. Finally,
for this patient, the 90Y-PET was used to calculate the
dose absorbed by the normal liver in order to plan a second
hepatic SIRT, more selective for the tumor. A good agree-
ment between 99mTc-MAA, bremsstrahlung, and 90Y-PET
imaging sessions was found for the four remaining patients.
Table 1 gives the total amount of activity in the liver for
the six patients and several reconstruction parameters in
light of theoretical injected activity as measured by the
dose calibrator. Measurement of initial activity was highly
unreliable [31] and was very difficult for the residualFigure 6 18 F-FDG PET and immuno-PET. Patient with follicular lymphoma in
scan after injection with 18 F-FDG and (B) immunoscintigraphy recorded
abnormal focus corresponding to a lymphoma mass detected on the pre
90Y-PET (bottom right).activity measurement. This was illustrated by the results
shown in Table 1 in which the reconstructed activity was
overestimated for one patient and underestimated for the
others, if one considers the correct activity to be that
measured by the dose calibrator.Discussion
This work addresses one aspect of the general question
of PET imaging with very low activity, such as that
encountered typically in PET monitoring of therapeutic
ion irradiation [32]. Here, we showed that although 90Y
imaging is possible, it is useful only for a size and con-
centration above a given level of radioactive concentra-
tion and when optimized parameters are implemented.
Previous work in the area of 90Y imaging by PET has
established this technique as being potentially useful for
the precise assessment of the spatial distribution of
microspheres and to determine the quantitative input
activity map for subsequent dosimetric calculations [15,17].
The advantage of using TOF vs. non-TOF reconstruction
has also been recently studied in a comprehensive manner
[19]. However, all these studies were conducted in the con-
text of therapeutic radioembolization with microspheres
[15,19] or PRRT [17]. This type of treatment results in a
radioactive concentration of several MBq mL−1 or even
tens of MBq mL−1 [17-19]. To our knowledge, no studies
have reported the calculation of the minimum detectable
radioactive concentration of 90Y by PET imaging, or its re-
lationship to lesion size and its impact on the quantification
of the signal. The current work was conducted in the
context of a systemic injection when the radioactive
concentrations are much smaller than SIRT, the ratio of
lesion to background is, in theory, high and the signaljected with 111In- and 90Y-ZevalinW (Bayer) 7 days apart. (A) Pre-therapeutic
6 days (bottom left) after 111In-ZevalinW (Bayer) injection showed an
-RAIT CT and 18 F-FDG PET (A). No relevant signal was detected by
Figure 7 Radioembolization images. Different imaging sessions for two patients (A and B) with HCC: 99mTc-MAA SPECT (left), bremsstrahlung
SPECT (center), and 90Y-PET (right). The reference lines cross a tumor lesion for the two patients. Imaging sessions for the second patient (B) show
a clear discrepancy between pre-therapeutic (left) and post-therapeutic (right) imaging sessions. Tumor uptake was detected with 90Y-PET (right)
but not with bremsstrahlung SPECT (center). Measurement of the tumor lesion for patient B is illustrated in red (right).
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order of magnitude as that obtained for low con-
centrations of 90Y.
The experimental data allowed us to determine some
practical aspects regarding the MDA or the influence of
reconstruction parameters on detectability and quantifi-
cation accuracy. Mainly, for lesions with an activity con-
centration exceeding 2 to 3 MBq mL−1, the best
detectability was provided by reconstruction using TOF
or non-TOF information with one iteration whatever the
lesion size. The TOF information and one iteration were
required for an activity concentration below 2 to 3 MBq -
mL−1 regardless of the lesion size, in terms of best
detectability. These results are consistent with thoseTable 1 Reconstructed activity




1 (TOF) 3 (TOF) 3 (nTOF)
1 2401 (+23%) 2515 (+28%) 2164 (+11%) 1958
2 1194 (−10%) 1374 (+3%) 1231 (−8%) 1332
3 468 (−9%) 534 (+4%) 428 (−17%) 514
4 324 (−23%) 361 (−14%) 348 (−17%) 422
5 1037 (−8%) 1090 (−3%) 1009 (−10%) 1124
6 638 (−19%) 721 (−8%) 659 (−16%) 784
Total reconstructed activity (MBq) for the six patients with HCC according to
reconstruction parameters. The relative differences between reconstructed
activity and activity measured before injection are in parentheses.reported previously in a context where the signal to
background ratio was one order of magnitude lower [19]
than in our work. Table 2 summarizes the estimated MDA
for all lesion sizes, showing that the best detectability was
effectively reached with one iteration (TOF or non-TOF).
Regarding the accuracy of quantitative information, the
best compromise was reached using TOF information and
three iterations regardless of the radioactive concentration
and lesion size.
These experimental findings were compared to those
derived in clinical situation and allowed a comprehen-
sive knowledge of the signal collected in patients.
We must emphasize that the signal from the 176Lu be-
came a significant contribution for random coincidences
for radioactive concentration below 1 MBq mL−1 in a
cold background (or with a high ratio between the signal
in the background and the spheres). After reconstruc-
tion, the residual signal resulted in multiple isolated foci
of moderate intensity in the reconstructed volume that
may increase the number of false positive results when
small lesions or low concentrations are involved. This
reconstructed signal is further amplified by the necessary
attenuation correction and appears more intense in the
reconstructed volume, especially when three iterations
are used. In this last case, the radioactive concentration
of a false positive could be in the range of few MBq mL−1
due to statistical fluctuations. Generally, when the concen-
tration measured in a lesion extracted from a volume
reconstructed with one iteration and TOF is greater












MDA for the different sphere and TOF reconstruction option.
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true positive even if the concentration measured in a vol-
ume reconstructed with TOF and three iterations is in the
range of few MBq mL−1. Conversely, a concentration
measured as high as few MBq mL−1 for a reconstructed
volume with TOF and three iterations but with an inten-
sity of less than few hundred of kBq mL−1, when the vol-
ume is reconstructed with one iteration and TOF, could
be considered as false positive. This effect was clearly
observed in the phantom measurements. This is a poten-
tial method to discriminate true positive from false posi-
tive in the context of clinical 90Y-PET imaging, but it still
needs to be confirmed on larger clinical datasets by
comparing it with 99mTc-MAA and contrast-enhanced
CT. Finally, unlike the hypothesis provided by Campbell
et al. [33] and van Elmbt et al. [19], we found a mean
tumor-to-liver uptake ratio of roughly 10 for patients
with HCC. This led to higher mean activity
concentrations of 10 MBq mL−1 in the tumor and ap-
proximately 900 kBq mL−1 (range 200 to 1,300 kBq mL−1)
in the liver, higher than those reported in the latter studies.
One of the main limitations of our study was the
estimated CNR based on the assumption of uncorrelated
noise and was generally assessed for data reconstructed
with linear algorithms such as FBP. The use of 3D OP-
OSEM and a PSF model within the chosen reconstruc-
tion method led to a correlation between voxels, which
may have affected the noise estimation. However, based
on the chosen parameters, we assumed that this effect
would be limited to the extent of 2 to 3 voxels only [34],
despite the post-smoothing Gaussian function (2 mm
FWHM) and could be neglected in this work. Moreover,
the definition of the limit of detectability of lesions (i.e.,
CNR > 8) is a complex function depending on the size
and shape of the lesion. The value chosen in this work
was adapted from a study with human observers within
a framework of simulated noisy micrographs [29]. The
limit used in this study does not necessarily reflect that
which is specific to PET imaging in a low count rate
with an iterative reconstruction. Assumptions related to
the Rose criterion [27] were probably not completely
fulfilled, but the quantitative results that we derived
were consistent with the visual analysis. Moreover, anadditional analysis (not shown) with a different limit of
CNR > 5 did not substantially modify the main conclusions
regarding detectability.
The CNR may also be significantly improved using a
Gaussian post-filtering with a higher FWHM value to
reduce noise in the reconstructed images [26] but at the
expense of a more pronounce correlation between voxels.
In this work, we have set the post-filtering strength to that
used for routine examinations of 18 F-FDG considering,
firstly, the improvement in the reconstructed spatial
resolution provided by the PSF modelling, and secondly
to reduce the bias in quantitation for the reconstructed
volume.
Regarding the estimation of scattered radiation, it
should be noted that it relies on a prior quick analytical
reconstruction uncorrected for scattering events [35]. As
these preliminary reconstructions are based on very
noisy sinograms, we expect as well the scattering simula-
tion may fail to calculate a reliable estimate. Similarly,
van Elmbt et al. [19] suggested an additional component
of true coincidences affecting the ends of the profile tails
of the rebinned sinograms. They assumed that this signal
may come from pair production in the LSO crystals by
the X-ray bremsstrahlung above 1.022 MeV. This com-
ponent may have an impact on the scaling of the
scattered sinogram to the emission sinogram. This uni-
form background may also affect the random correction
process, but no specific correction was applied to ac-
count for.
Finally, we used a single acquisition for the extraction
of figures of merit used in this work. The use of multiple
independent acquisitions for each of the measuring
points would have certainly strengthened the statistical
robustness of each measurement, especially when the
radioactive concentration in the spheres was less than 1 -
MBq mL−1. We reasonably assume that the use of experi-
mental replicates does not change the basic conclusions of
this work.
Conclusions
This study assessed the MDA for a 30-min 90Y-PET im-
aging session and the accuracy of reconstructed activity
concentration according to lesion size and its concentra-
tion. The benefit of using TOF information is discussed
and shown for concentrations below 2 MBq mL−1 or
small lesion size. An activity concentration below 1 MBq -
mL−1 may be detected but with a variable quantitative
accuracy depending on the lesion size and reconstruc-
tion parameters. 90Y-PET imaging is probably not feas-
ible for most RAIT procedures due to the very low
uptake by the lesions during this type of treatment.
However, the utility of 90Y-PET imaging after SIRT in
hepatic tumors was demonstrated and could be an op-
portunity to retrospectively check the distribution of
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ately compute the absorbed dose.
Finally, future developments will be dedicated to a better
understanding of the physics and imaging properties of
90Y image and data, a further specialization of the acquisi-
tion protocols, and derive adequate correction schemes.
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